

# Shorter Weaning From Invasive Ventilation With Levosimendan

NCT07105202

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	Radboud University Medical Center
<b>Enrollment</b>	250 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Invasively ventilated  $\geq$  48 hours.
- Failed at least one spontaneous breathing trial (SBT).
- Age above 18 years.
- Female patients with age  $<$  60 must have a negative pregnancy test (blood or urine) prior to participation.

### Exclusion (7)

- Pre-existing neuromuscular disease (congenital or acquired)
- Endotracheally intubated primarily for neurological reason (e.g., traumatic brain injury, intracranial haemorrhage, epilepsy, intracranial infection), or developed severe intracranial haemorrhage/infarction during ICU stay.
- Contra-indications for levosimendan: severe renal failure (creatinine clearance  $<$ 30mL/min) unless managed with appropriate continuous kidney replacement therapy (such as CRRT), severe liver failure (Child-Pugh class C), history of torsade des pointes; known significant mechanical obstructions affecting ventricular filling/ outflow or both; prolonged QTc interval (QTc  $>$  470ms); breast feeding; known hypersensitivity to levosimendan.
- Treatment with intermittent haemodialysis.
- Treatment limitation decision in place: do not reintubate

... and 2 more (see full listing online)

## Locations (8 total)

---

Rijnstate Ziekenhuis Stichting, Arnhem, Gelderland, Netherlands  
Intensive Care Medicine, Radboud University, Nijmegen, Gelderland, Netherlands  
Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands  
... and 5 more locations